S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00040937
Completed
RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving thalidomide before and after peripheral stem cell transplant may be effective in treating newly diagnosed multiple myeloma. PURPO... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/26/2016
Locations: Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas +140 locations
Conditions: Multiple Myeloma
Register for Updates
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
NCT00429416
Completed
The purpose of this research study is to determine if an experimental agent, LLME can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following blood (hematopoietic) stem cell transplantation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2016
Locations: Thomas Jefferson University', Philadelphia, Pennsylvania
Conditions: Hematologic Malignancies
Register for Updates
Multicenter Uveitis Steroid Treatment (MUST) Trial
NCT00132691
Completed
The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
10/13/2016
Locations: Jacobs Retina Center, UCSD, La Jolla, California +22 locations
Conditions: Uveitis
Register for Updates
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
NCT00901069
Completed
This is a phase I, prospective, open label, dose escalation study of azacitidine in combination with rituximab, vincristine, and cyclophosphamide for the treatment of refractory lymphoma. The investigators expect to enroll 12-24 patients in this trial over a 2 year accrual period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2016
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin
Register for Updates
Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
NCT00003899
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of melphalan and thiotepa plus bone marrow or peripheral stem cell transplantation in treating patients who have recurrent or refractory solid tumors.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/03/2016
Locations: Fred Hutchinson Cancer Research Center, Seattle, Washington
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
NCT01527487
Completed
The investigators propose a randomized phase II study evaluating the pCR and toxicity profiles of combination eribulin/cyclophosphamide (ErC) and docetaxel /cyclophosphamide (TC) as neoadjuvant therapy for locally advanced HER2-negative breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/03/2016
Locations: Florida Cancer Specialists South, Ft. Myers, Florida +14 locations
Conditions: HER2 Negative Breast Cancer
Register for Updates
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
NCT00255684
Terminated
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
09/28/2016
Locations: James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York
Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Register for Updates
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
NCT01498588
Terminated
Previous studies have shown that chemotherapy has the same effect on treating breast cancer whether you receive it before or after surgery. Receiving chemotherapy before surgery, rather than after surgery, may allow the patient to have less extensive surgery. The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of eribulin followed by doxorubicin and cyclophosphamide can shrink the size of the patient's breast tumor and all... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2016
Locations: Grady Memorial Hospital, Atlanta, Georgia +3 locations
Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast
Register for Updates
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
NCT00021255
Completed
Primary objective: * Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin. Secondary objective: * Compare overall survival of participants treated with these regimens. * Compare the toxic effects (including cardiac) of these regi... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
09/26/2016
Locations: Sanofi-Aventis Administrative Office, Bridgewater, New Jersey +41 locations
Conditions: Breast Neoplasms
Register for Updates
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
NCT00634179
Completed
This is an open-label (doctors and patients know which drug will be given), single center, phase 1/2 clinical trial. The primary objective is to determine whether VR-CHOP provides benefit to patients with previously untreated indolent non-Hodgkin's lymphomas (NHL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/21/2016
Locations: Emory University Winship Cancer Institute, Atlanta, Georgia
Conditions: Lymphoma, B-Cell, Follicular Lymphoma
Register for Updates
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients
NCT00254163
Completed
The purpose of this research study is to find out what effects (good and bad) the combination of Nipent+Cytoxan+Rituxan has on CLL cancer compared to Fludara+Cytoxan+Rituxan. While all of these drugs are approved by the Food and Drug Administration (FDA) for the treatment of other cancers, these combinations are experimental for the treatment of CLL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/15/2016
Locations: Cancer Centers of Florida, P.A., Ocoee, Florida +10 locations
Conditions: B-Cell Chronic Lymphocytic Leukemia
Register for Updates
Adj TC + Herceptin Early Stage Breast Cancer
NCT00493649
Completed
The purpose of this research study is to find out what effects (good and bad) docetaxel/cyclophosphamide (brand names: Taxotere and Cytoxan, or TC) plus trastuzumab (brand name: Herceptin, or H) has HER2+ breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
09/15/2016
Locations: Birmingham Hematology and Oncology, Birmingham, Alabama +68 locations
Conditions: Breast Cancer
Register for Updates